Sana Biotechnology (NASDAQ:SANA) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the company. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Citigroup boosted their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, August 9th.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA opened at $2.55 on Wednesday. The company has a market capitalization of $569.34 million, a P/E ratio of -1.82 and a beta of 1.44. The company has a 50-day simple moving average of $3.61 and a 200 day simple moving average of $5.21. Sana Biotechnology has a 52-week low of $2.29 and a 52-week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. As a group, equities analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the transaction, the director now owns 2,848,121 shares in the company, valued at $11,620,333.68. This represents a 5.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 31.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sana Biotechnology

Institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Sana Biotechnology in the 3rd quarter worth approximately $29,000. Stifel Financial Corp bought a new stake in shares of Sana Biotechnology in the third quarter valued at $43,000. EP Wealth Advisors LLC purchased a new position in shares of Sana Biotechnology during the 3rd quarter valued at $45,000. Blue Trust Inc. grew its stake in shares of Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after acquiring an additional 12,154 shares during the period. Finally, Algert Global LLC purchased a new stake in Sana Biotechnology in the 2nd quarter worth about $73,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.